Secondary Osteosarcoma Developing 10 Years after Chemoradiotherapy for Non-small-cell Lung Cancer
Shigehiro Yagishita, T Tamura(National Cancer Center), Tomoko Yorozu(Kyorin University), Hiroshi Nokihara(Tokushima University Hospital), Nobuyuki Yamamoto(Wakayama Medical University), Minako Sumi(Tokyo Metropolitan Geriatric Hospital), Satoru Kitazono(The Cancer Institute Hospital), Yutaka Fujiwara(Aichi Cancer Center), Hidehito Horinouchi(Tokyo National Hospital), Takuya Mori(National Cancer Center), Shintaro Kanda(Shinshu University Hospital), K. Tsuta(National Cancer Center), Hidenori Mizugaki(Hokkaido University)
Cited by 2
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
|The Lancet Oncology|2015|980
Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|365